Recent News

• 03.04.2026 - Cellectar Biosciences Reports Financial Results for Year Ended 2025 and Provides Corporate Updates
• 02.25.2026 - Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Wednesday, March 4, 2026
• 02.17.2026 - Cellectar Biosciences Expands Global Intellectual Property Estate
• 01.09.2026 - Cellectar Biosciences to Highlight Strategic Initiatives for 2026 at Upcoming Biotech Showcase during 44th Annual JP Morgan Healthcare Conference
• 12.16.2025 - Cellectar Biosciences Announces Strategic Supply Agreement with Ionetix for Actinium-225 and Astatine-211 to Advance Targeted Alpha Therapies
• 11.13.2025 - Cellectar Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update
• 11.06.2025 - Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Thursday, November 13, 2025
• 10.27.2025 - Cellectar Biosciences Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Iopofosine I 131 in Relapsed or Refractory Pediatric High-Grade Glioma
• 10.14.2025 - Cellectar Biosciences Presented Promising Preclinical Data in Poster Presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research

Recent Filings

• 02.13.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.10.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.04.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 12.16.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.21.2025 - 424B3 Prospectus [Rule 424(b)(3)]
• 11.14.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 11.13.2025 - EX-99.1 EX-99.1
• 11.13.2025 - 8-K Current report
• 11.13.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 10.20.2025 - S-1 General form for registration of securities under the Securities Act of 1933